Therapeutic Area: Oncology

Connecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer

Wang et al.
Nature Immunology
July 2019
Authors and Affiliates
Wang L1, Simons DL1, Lu X2, Tu TY1, Solomon S1, Wang R1, Rosario A1, Avalos C1, Schmolze D3, Yim J4, Waisman J5, Lee PP6.; 1 Department of Immuno-Oncology, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. 2 Department of Biostatistics, University of California, Los Angeles, Los Angeles, CA, USA. 3 Department of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. 4 Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. 5 Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. 6 Department of Immuno-Oncology, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. plee@coh.org.

CRISPR genome editing of murine hematopoietic stem cells to create Npm1-Alk causes ALK1 lymphoma after transplantation

Rajan et al.
Blood Advances
June 2019
Authors and Affiliates
Rajan SS1,2, Li L2,3, Kweh MF2,3, Kunkalla K2,4, Amin AD2,3, Agarwal NK2,4, Vega F2,4, Schatz JH2,3; Author information 1 Sheila and David Fuente Graduate Program in Cancer Biology. 2 Sylvester Comprehensive Cancer Center. 3 Division of Hematology, Department of Medicine, and. 4 Division of Hematopathology, Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL

T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant

Chapuis et al.
Nature Medicine
June 2019
Authors and Affiliates
Chapuis AG1,2,3, Egan DN2,3, Bar M2,3, Schmitt TM1,2, McAfee MS1,2, Paulson KG1,2,3, Voillet V4, Gottardo R4,5, Ragnarsson GB1,2,6, Bleakley M1,2,3, Yeung CC2,3, Muhlhauser P3, Nguyen HN1,7, Kropp LA1,2,8, Castelli L1,2,8, Wagener F1,2, Hunter D1,2, Lindberg M1,2,9, Cohen K4, Seese A4, McElrath MJ2,3,4, Duerkopp N1,2, Gooley TA2,5, Greenberg PD10,11,12,13. Author information 1 Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 2 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 3 University of Washington School of Medicine, Seattle, WA, USA. 4 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 5 Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 6 Landspítali Háskólasjúkrahús, Reykjavík, Iceland. 7 Alpine Biotech, Seattle, WA, USA. 8 Therapeutic Products Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 9 School of Informatics, University of Edinburgh, Edinburgh, UK. 10 Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. pgreen@u.washington.edu. 11 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. pgreen@u.washington.edu. 12 University of Washington School of Medicine, Seattle, WA, USA. pgreen@u.washington.edu. 13 Departments of Immunology and Medicine, University of Washington, Seattle, WA, USA. pgreen@u.washington.edu.

Defining Virus-specific CD8+ TCR Repertoires for Therapeutic Regeneration of T Cells against Chronic Hepatitis E

Soon et al.
Journal of Hepatology
June 2019
Authors and Affiliates
Soon CF1, Behrendt P2, Todt D3, Manns MP1, Wedemeyer H4, Sällberg Chen M5, Cornberg M6. Author information 1 Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany. 2 Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; German Center for Infection Research (DZIF), partner site Hannover, Braunschweig, Germany; Institute for Experimental Virology, TWINCORE Centre for Experimental and Clinical Infection Research. 3 Department for Molecular and Medical Virology, Ruhr-Universität Bochum, Bochum, Germany. 4 Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; German Center for Infection Research (DZIF), partner site Hannover, Braunschweig, Germany; Department of Gastroenterology and Hepatology, University Clinic Essen, Essen, Germany. 5 Department of Dental Medicine and Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. 6 Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; German Center for Infection Research (DZIF), partner site Hannover, Braunschweig, Germany; Centre for Individualised Infection Medicine (CIIM), Hannover, Germany; Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany. Electronic address: Cornberg.Markus@mh-hannover.de.

Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity

Kuehm et al.
Cancer Immunology and Immunotherapy
May 2019
Authors and Affiliates
Kuehm LM1, Wolf K1, Zahour J1, DiPaolo RJ1,2, Teague RM3,4; 1 Molecular Microbiology and Immunology Department, Saint Louis University School of Medicine, 1100 South Grand Blvd, St. Louis, MO, 63104, USA. 2 Alvin J. Siteman National Cancer Institute Comprehensive Cancer Center, St. Louis, MO, USA. 3 Molecular Microbiology and Immunology Department, Saint Louis University School of Medicine, 1100 South Grand Blvd, St. Louis, MO, 63104, USA. ryan.teague@health.slu.edu. 4 Alvin J. Siteman National Cancer Institute Comprehensive Cancer Center, St. Louis, MO, USA. ryan.teague@health.slu.edu.

Human urothelial bladder cancer generates a clonal immune response: The results of T-cell receptor sequencing

Sankin et al.
Urologic Oncology
May 2019
immuneAccess
Authors and Affiliates
Sankin A1, Chand D2, Schoenberg M3, Zang X2. 1 Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY. Electronic address: asankin@montefiore.org. 2 Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY; Department of Microbiology and Immunology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY. 3 Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

Voorwerk et al.
Nature Medicine
May 2019
Authors and Affiliates
Voorwerk L1, Slagter M1,2,3, Horlings HM4, Sikorska K5, van de Vijver KK4,6, de Maaker M7, Nederlof I7, Kluin RJC8, Warren S9, Ong S9, Wiersma TG10, Russell NS10, Lalezari F11, Schouten PC7, Bakker NAM3,12, Ketelaars SLC1, Peters D13, Lange CAH11, van Werkhoven E5, van Tinteren H5, Mandjes IAM5, Kemper I14, Onderwater S14, Chalabi M1,15, Wilgenhof S14, Haanen JBAG1,14, Salgado R16,17, de Visser KE3,12, Sonke GS14, Wessels LFA2,3, Linn SC7,14, Schumacher TN1,3, Blank CU1,14, Kok M18,19. 1 Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 2 Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 3 Oncode Institute, Utrecht, the Netherlands. 4 Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 5 Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 6 Department of Pathology, Ghent University Hospital, Ghent, Belgium. 7 Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 8 Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 9 NanoString Technologies, Inc., Seattle, WA, USA. 10 Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 11 Department of Radiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 12 Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 13 Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 14 Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 15 Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 16 Department of Pathology, GZA-ZNA Ziekenhuizen, Antwerp, Belgium. 17 Division of Research, Peter Mac Callum Cancer Center, Melbourne, Victoria, Australia. 18 Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. m.kok@nki.nl. 19 Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. m.kok@nki.nl.

Rational design of anti-GITR-based combination immunotherapy

Zappasodi et al.
Nature Medicine
April 2019
immuneAccess
Authors and Affiliates
Zappasodi R1,2, Sirard C3, Li Y1,2, Budhu S1, Abu-Akeel M1, Liu C1, Yang X1, Zhong H1, Newman W3, Qi J2,4, Wong P2,4, Schaer D1, Koon H5, Velcheti V6, Hellmann MD2,7,8, Postow MA7,8, Callahan MK2,7,8, Wolchok JD9,10,11,12, Merghoub T13,14,15; Author information 1 Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2 Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3 Leap Therapeutics, Cambridge, MA, USA. 4 Immune Monitoring Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5 Case Western Reserve University, Cleveland, OH, USA. 6 Department of Hematology and Oncology, New York University School of Medicine, New York, NY, USA. 7 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 8 Weill Cornell Medical College, New York, NY, USA. 9 Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA. wolchokj@mskcc.org. 10 Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. wolchokj@mskcc.org. 11 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. wolchokj@mskcc.org. 12 Weill Cornell Medical College, New York, NY, USA. wolchokj@mskcc.org. 13 Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA. merghout@mskcc.org. 14 Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. merghout@mskcc.org. 15 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. merghout@mskcc.org.

Immunogenic neoantigens derived from gene fusions stimulate T cell responses

Yang et al.
Nature Medicine
April 2019
Authors and Affiliates
Yang W1,2, Lee KW1, Srivastava RM2, Kuo F2, Krishna C3, Chowell D2, Makarov V2, Hoen D2, Dalin MG4, Wexler L5, Ghossein R6, Katabi N6, Nadeem Z7, Cohen MA7, Tian SK8, Robine N8, Arora K8, Geiger H8, Agius P8, Bouvier N9, Huberman K9, Vanness K9, Havel JJ1,2, Sims JS2, Samstein RM10, Mandal R2,7, Tepe J7, Ganly I7, Ho AL11, Riaz N2,10, Wong RJ7, Shukla N6, Chan TA12,13,14, Morris LGT15,16,17; 1 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2 Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3 Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4 Department of Pediatrics, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden. 5 Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 7 Department of Surgery (Head and Neck Service), Memorial Sloan Kettering Cancer Center, New York, NY, USA. 8 New York Genome Center, New York, NY, USA. 9 Integrated Genomics Operation, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 10 Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 11 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 12 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. chant@mskcc.org. 13 Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA. chant@mskcc.org. 14 Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. chant@mskcc.org. 15 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. morrisl@mskcc.org. 16 Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA. morrisl@mskcc.org. 17 Department of Surgery (Head and Neck Service), Memorial Sloan Kettering Cancer Center, New York, NY, USA. morrisl@mskcc.org.

Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States

Wei et al.
Immunity
April 2019
immuneAccess
Authors and Affiliates
Wei SC1, Sharma R2, Anang NAS1, Levine JH3, Zhao Y4, Mancuso JJ1, Setty M3, Sharma P5, Wang J4, Pe'er D6, Allison JP7; 1Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 2 Computational and Systems Biology Program, Sloan Kettering Institute, New York, NY 10065, USA; Department of Applied Physics and Applied Mathematics, Columbia University, New York, NY 10027, USA. 3 Computational and Systems Biology Program, Sloan Kettering Institute, New York, NY 10065, USA. 4 Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 5 Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Parker Institute for Cancer Immunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 6 Computational and Systems Biology Program, Sloan Kettering Institute, New York, NY 10065, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. 7 Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Parker Institute for Cancer Immunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: jallison@mdanderson.org.